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Abstract
Background: Use of local corticosteroids, especially the in-
haled types, has increasingly been associated with systemic 
uptake and consequent adverse effects. In this study, we as-
sessed the associations between the use of different cortico-
steroid types with cognitive and neuropsychiatric adverse 
effects related to high glucocorticoid exposure. Methods: In 
83,592 adults (mean age 44 years, 59% women) of the gen-
eral population (Lifelines Cohort Study), we analyzed the re-
lationship between corticosteroid use with executive cogni-
tive functioning (Ruff Figural Fluency Test), and presence of 
mood and anxiety disorders (Mini-International Neuropsy-
chiatric Interview survey). We performed additional explora-
tion for effects of physical quality of life (QoL; RAND-36), and 
inflammation (high-sensitive C-reactive protein [CRP]). Re-
sults: Cognitive scores were lower among corticosteroid us-
ers, in particular of systemic and inhaled types, when com-
pared to nonusers. Users of inhaled types showed lower cog-
nitive scores irrespective of physical QoL, psychiatric 
disorders, and high-sensitive CRP. Overall corticosteroid use 
was also associated with higher likelihood for mood and anx-
iety disorders. Users of inhaled corticosteroids were more 
likely to have mood disorders (OR 1.40 [95% CI 1.19–1.65], 
p < 0.001) and anxiety disorders (OR 1.19 [95% CI 1.06–1.33], 
p = 0.002). These findings were independent of physical QoL. 
A higher likelihood for mood disorders was also found for 
systemic users whereas nasal and dermal corticosteroid us-
ers were more likely to have anxiety disorders. Conclusions: 
Commonly used local corticosteroids, in particular inhaled 
types, and systemic corticosteroids are associated with re-
duced executive cognitive functioning and a higher likeli-
hood of mood and anxiety disorders in the general adult 
population. © 2019 The Author(s)
Published by S. Karger AG, Basel
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Introduction
Adverse effects of the glucocorticoid cortisol are usu-
ally observed in case of supraphysiological exposure as 
seen in patients with endogenous or exogenous Cushing’s 
syndrome. Given the extent of cortisol action, high levels 
can lead to various physical as well as mental alterations. 
Cushing’s syndrome patients, for example, develop obe-
sity, hypertension, menstrual irregularities, and neuro-
psychiatric pathologies [1]. The incidence of endogenous 
Cushing’s syndrome is extremely low with approximate-
ly 1–2 new cases per million persons annually [2]. How-
ever, the main cause of excessive glucocorticoid exposure 
is due to exogenous administration of drugs containing 
synthetic glucocorticoids [3]. These corticosteroids are 
one of the most prescribed drugs given their high anti-
inflammatory and immunomodulatory potential, and 
many indications. Besides, the availability of corticoste-
roids in many systemic and local administration formula-
tions makes them readily feasible and convenient for clin-
ical use. We previously showed that nearly 11% of the 
adults of the general population of the Netherlands was 
using any type of corticosteroid, which is comparable 
with prescription numbers in ambulatory care in the 
United States [4].
The common assumption is that only systemic corti-
costeroid variants can induce systemic adverse events, 
and that the effects of the local forms are generally lim-
ited to the application site. However, mounting evidence 
is questioning this notion. A large meta-analysis, for ex-
ample, demonstrated an increased risk of adrenal insuf-
ficiency also with local corticosteroid forms [5]. More-
over, we previously demonstrated that users of systemic 
corticosteroids as well as the local forms, in particular of 
the inhaled types, were more likely to have metabolic syn-
drome, increased waist circumference, higher body mass 
index (BMI), and other adverse cardiometabolic derange-
ments in comparison to nonusers [6]. Both increased ad-
renal insufficiency risk and higher likelihood of frequent 
corticosteroid-related metabolic effects in local cortico-
steroid users support the idea of systemic absorption and 
subsequent systemic adverse effects of local corticoste-
roids. In this regard, it would be reasonable to also expect 
effects on the brain in the case of systemic availability of 
these types. Despite previous studies observing cognitive 
impairments [7, 8] and psychiatric disorders [9] in en-
dogenous Cushing’s syndrome patients and systemic cor-
ticosteroid users [10], there are, to our knowledge, no 
large population-based studies that have investigated the 
associations between cognitive and psychiatric indices 
and use of the various local corticosteroid types. In this 
study, we therefore assessed the relationship of systemic 
and local corticosteroid use with cognition and neuropsy-
chiatric health in the general adult population. 
Subjects and Methods
Study Population
We included data of adult participants of the Lifelines research 
program, which is a multi-disciplinary prospective population-
based cohort study examining in a unique 3-generation design the 
health and health-related behaviors of 167,729 persons living in 
the north of The Netherlands. It employs a broad range of investi-
gative procedures in assessing the biomedical, socio-demographic, 
behavioral, physical and psychological factors that contribute to 
the health and disease of the general population, with a special fo-
cus on multi-morbidity and complex genetics [11]. Participants 
were included in case of complete data regarding outcomes of the 
assessment for cognitive functioning, neuropsychiatric health, and 
physical quality of life (QoL). After exclusion of participants with 
inconclusive information on drug use, there were in total 83,592 
subjects eligible for the current study. 
Corticosteroid Use
Current drug use was assessed by questionnaire and on-site 
inspection of drug containers. Drugs were subsequently coded ac-
cording to their corresponding WHO Anatomical Therapeutic 
Chemical code. We filtered users of any type of corticosteroid and 
grouped them as being “corticosteroid users.” Drugs with only 
mineralocorticoid action were not included. Subclassification was 
made for users of only local administration forms or users of sys-
temic corticosteroids (i.e., oral and/or parenteral) with or without 
any of the other types. To elaborate the associations with specific 
administration forms, we further classified single-type users ac-
cording to their use of only systemic, inhaled, nasal, dermal or 
other (i.e., otological, ocular, intestinal, local-oral, hemorrhoidal, 
or gynaecological) types. 
Cognitive Functioning
The Ruff Figural Fluency Test (RFFT) is a measure of nonver-
bal fluency as part of executive cognitive functioning. The test con-
tains 5 sheets each consisting of 35 identical frames of 5-dot pat-
terns with or without distracting elements. For each part, partici-
pants are instructed to connect 2 or more dots per frame with 
straight lines and to make as many as possible unique designs with-
out falling into repetition in 1 min [12]. The primary outcome is 
the total number of unique designs (i.e., unique design score), 
which can range from 0 to 175. The test was not performed in sub-
jects who were consistently unable to properly hold a pen, had im-
paired vision, a score below 26 on the Mini-Mental State Examina-
tion, or had performed the test previously in another cohort study. 
Neuropsychiatric Assessment
The Mini-International Neuropsychiatric Interview is a struc-
tured interview intended for diagnosing psychiatric disorders ac-
cording to DSM-IV and ICD-10 diagnostic criteria [13]. Trained 
professionals administered the modules regarding the current di-
agnosis of major depressive episode, dysthymia, social phobia, 
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generalized anxiety disorder, agoraphobia without a history of 
panic disorder, and lifetime presence of panic disorder with or 
without agoraphobia. Patients were categorized as having a mood 
disorder if they met the diagnostic criteria for major depressive 
episode or dysthymia. Anxiety disorder was deemed present in 
case of any of the other assessed diagnoses. 
Physical QoL
Due to potential confounding by disease burden, we planned 
to perform subgroup analyses with stratification for health-related 
QoL. For this purpose, we used the outcomes of the RAND-36 
questionnaire, which is a commonly used survey consisting of 36 
questions related to own health status. A weighted scoring and 
Table 1. Characteristics of study sample
All
(n = 83,592)
Corticosteroid use
nonusers
(n = 74,591)
users
(n = 9,001)
Demographics
Age, yearsa 44.2±12.3 44.1±12.3 45.2±12.6
Sex, femalea 49,174 (58.8) 43,512 (58.3) 5,662 (62.9)
Educational attainmenta
Low 24,752 (29.6) 21,998 (29.5) 2,754 (30.6)
Middle 32,879 (39.3) 29,491 (39.5) 3,388 (37.6)
High 24,424 (29.2) 21,747 (29.2) 2,677 (29.7)
Other 1,537 (1.8) 1,355 (1.8) 182 (2.0)
Use of psychotropic drugsa 7,441 (8.9) 6,331 (8.5) 1,110 (12.3)
High-sensitive CRP, mg/La, b 1.20 (2.20) 1.20 (2.10) 1.50 (2.90)
Lifestyle
Physical activity
0 days per week 4,071 (4.9) 3,628 (4.9) 443 (4.9)
1–4 days per week 38,632 (46.2) 34,568 (46.3) 4,064 (45.2)
≥5 days per week 40,889 (48.9) 36,395 (48.8) 4,494 (49.9)
Smokinga
Nonsmoker 38,790 (46.4) 34,428 (46.2) 4,362 (48.5)
Former smoker 26,098 (31.2) 23,095 (31.0) 3,003 (33.4)
Current smoker 18,704 (22.4) 17,068 (22.9) 1,636 (18.2)
Alcohol usea
None 18,490 (22.1) 16,310 (21.9) 2,180 (24.2)
≤1 drink/day 41,161 (49.2) 36,701 (49.2) 4,460 (49.6)
1–2 drinks/day 17,049 (20.4) 15,356 (20.6) 1,693 (18.8)
>2 drinks/day 6,892 (8.3) 6,224 (8.3) 668 (7.4)
Cardiometabolic features
BMI, kg/m2a 26.1±4.3 26.0±4.3 26.7±4.8
Cardiovascular diseasesa 1,762 (2.1) 1,526 (2.0) 236 (2.6)
Strokea 555 (0.7) 481 (0.6) 74 (0.8)
Coronary heart diseasea 1,253 (1.5) 1,084 (1.5) 169 (1.9)
Ruf figural fluency test (executive cognitive functioning)
Unique designsa 81.3±23.3 81.5±23.3 79.9±23.4
MINI (psychiatric disorders)
Mood and/or anxiety disordersa 9,301 (11.1) 8,064 (10.8) 1,237 (13.7)
Mood disordersa 2,802 (3.4) 2,393 (3.2) 409 (4.5)
Anxiety disordersa 8,212 (9.8) 7,138 (9.6) 1,074 (11.9)
RAND36 (health-related quality of life)
Physical component summary scorea 52.9±7.5 53.3±7.2 50.3±9.0
All values are depicted as median (interquartile range), mean ± SD, or numbers (percentage). BMI, body mass index; CRP, C-reactive 
protein. a Significant crude differences between nonusers and users; b data on high-sensitive CRP were available in 45,395 participants 
including 40,695 nonusers and 4,700 users.
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summation of selected items results in a score between 0 and 100 
for 8 different domains [14]. By calculating the Z-score for each 
domain using Dutch reference population [15], we computed the 
aggregated physical component summary score [16] as a proxy for 
physical QoL. A higher score corresponds to a better QoL. 
Covariates
To minimize confounding, we included potential covariates 
based on literature, biological plausibility, and statistical signifi-
cance. Besides age and sex, we assessed self-reported educational 
attainment classified as low (i.e., no education, primary, lower or 
preparatory vocational education, and lower general secondary 
education), middle (i.e., intermediate vocational education or ap-
prenticeship, and higher general secondary education or pre-uni-
versity secondary education), high (i.e., higher vocational educa-
tion, and university), and other. The use of psychotropic drugs was 
evaluated by screening current drug use for antiepileptics (ATC 
group N03), psycholeptics (N05; e.g., antipsychotics, anxiolytics), 
and/or psychoanaleptics (N06; e.g., antidepressants, psychostimu-
lants). Lifestyle factors including physical activity, smoking, and 
alcohol use were assessed as previously described [6]. With regard 
to cardiometabolic factors, we included data on BMI, and presence 
of cardiovascular diseases. Trained technicians measured body 
weight (kg), and height (cm). Weight and height were used to com-
pute BMI (kg/m2). For cardiovascular diseases, subjects were asked 
to report if they had a past event of stroke, myocardial infarction, 
balloon angioplasty, and/or coronary artery bypass grafting. Any 
of the latter 3 conditions are also presented as coronary heart dis-
eases in the results. Data of some covariates were missing for < 5% 
of the subjects, however, this was higher for physical activity 
(6.8%), smoking (7.0%), and alcohol use (9.1%). 
Statistical Analysis
Differences in descriptive characteristics between users and 
nonusers were analyzed with Student t test or Mann-Whitney U 
test for continuous variables, and chi-square test for categorical 
data. Concerning the cognitive outcome, we performed analyses of 
covariance to assess differences in unique design score (RFFT anal-
ysis) between different routes of administration and for single-type 
users versus nonusers. We first analyzed crude differences, fol-
lowed by adjustments for age, and sex. In the main model, we ad-
ditionally adjusted for educational attainment, BMI, smoking, al-
cohol use, physical activity, cardiovascular diseases, and use of psy-
chotropic drugs. The differences between users and nonusers in 
the binary outcomes for presence or absence of psychiatric disor-
ders were assessed with logistic regression analyses. We performed 
similar adjustments for these analyses, and reported the crude and 
fully adjusted results. Interaction effects with sex and age were as-
sessed in main analyses with complete group. With respect to dis-
ease burden, we additionally performed stratified analysis by either 
low (≤ median) or high (> median) physical component summary 
score. Moreover, given the recent finding that the unique design 
score is associated with anxiety and depression [17] we addition-
ally repeated the analyses for cognitive functioning separately in 
participants with and without any of the assessed psychiatric dis-
orders. IBM SPSS Statistics version 22.0.0.2 (IBM Corp., Armonk, 
NY, USA) was used to carry out multiple imputations for covari-
ates with missing data, and to perform all analyses (2-sided). p val-
ues below 0.050 were considered statistically significant. 
Sensitivity Analyses
Since corticosteroids are generally used in the presence of inflam-
matory processes and given the potential effect of inflammation on 
mental health and functioning, we performed sensitivity analyses to 
evaluate the relationship between the inflammatory marker C-reac-
tive protein (CRP) with our outcomes and whether this contributed 
to the differences between users and nonusers. High-sensitive CRP 
(hsCRP) was measured with an immuno-nephelometric assay (Car-
dioPhase hsCRP, Siemens Healthcare Diagnostics, Marburg, Ger-
many). Data were available of 45,395 subjects of whom 89.6% were 
nonusers and 10.4% users. Coefficients were assessed in the main 
models for both cognition and psychiatric disorders.
Results
Subject Characteristics
Characteristics of the study population as a whole and 
stratified for corticosteroid use are shown in Table 1. Sub-
jects were on average 44.2 years old and 58.8% were wom-
en. Corticosteroids were being used by 10.8% of the study 
Systemic corticosteroids 
Inhaled corticosteroids 
Nasal corticosteroids 
Dermal corticosteroids 
Other corticosteroids 
80 %  s ingle-type u s
ers
50% single-type use
rs
n = 4,471
n = 3,260
n = 2,087
n = 393n = 369
Fig. 1. Distribution of corticosteroid use in the study sample. Super-
imposed pie chart illustrating for each corticosteroid type the total 
number of users and the proportion of single-type use. The former 
is presented as the size of each slice and is also written in text beside. 
The radial length marks the percentage of users within each type who 
were not using any other corticosteroid types. These groups of sin-
gle-type users were used to assess the associations for the specific 
administration forms. Single-type use was most prevalent in dermal 
corticosteroid users (77.6%) while nasal corticosteroids were rela-
tively most often combined with other types of corticosteroids. 
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population, which largely consisted of users of inhaled 
corticosteroids. The majority of users of the different ad-
ministration forms were single-type users (Fig. 1). Physi-
cal QoL was higher in nonusers in comparison to users 
(53.3 [±7.2] vs. 50.3 [±9.0], p < 0.001). 
Corticosteroid Use and Executive Cognitive 
Functioning
The total unique design score was 81.3 (±23.3) in the 
total study population. Overall corticosteroid use was as-
sociated with a 1.6 (95% CI 1.1–2.1, p < 0.001) lower cogni-
tive score, which remained statistically significant after full 
adjustments of all specified covariates. Users of only local 
types and users of systemic (with or without local cortico-
steroids) had a lower score in comparison to nonusers (–0.9 
[–1.4 to –0.4], p < 0.001; –3.0 [–5.1 to –1.0], p = 
0.004 respectively). Within single-type users, only systemic 
corticosteroid users (–2.9 [–5.3 to –0.4], p = 0.024) and in-
haled corticosteroid users (–2.1 [–2.9 to –1.4], p < 0.001) 
scored lower in unique design score when compared to 
non-corticosteroid users. Subgroup analyses stratified for 
either low or high physical QoL and for presence or absence 
of mood and/or anxiety disorders revealed consistently 
lower scores in inhaled corticosteroid users compared to 
nonusers (Fig. 2). With respect to other forms, only the use 
of systemic corticosteroids was associated with a significant 
lower score in subjects without mood and anxiety disorders 
(–3.1 [–5.8 to –0.5], p = 0.021), whereas no significant dif-
ferences were found for the remaining types. No interac-
tion with sex or age was observed.
Others
Dermal
Nasal
Inhaled
Systemic
Others
Dermal
Nasal
Inhaled
Systemic
−8 −4 840 −8 −4 840
Others
Dermal
Nasal
Inhaled
Systemic
Overall
Low physical QoL High physical QoL
Mood and/or anxiety disorder present No mood or anxiety disorder
a
b
c
(n = 280)
(n = 3,248)
(n = 2,142)
(n = 1,620)
(n = 263)
(n = 238)
(n = 2,248)
(n = 1,212)
(n = 882)
(n = 170)
(n = 37)
(n = 490)
(n = 281)
(n = 194)
(n = 34)
Others
Dermal
Nasal
Inhaled
Systemic
Others
Dermal
Nasal
Inhaled
Systemic
(n = 42)
(n = 1,000)
(n = 930)
(n = 738)
(n = 93)
(n = 243)
(n = 2,758)
(n = 1,861)
(n = 1,426)
(n = 229)
Fig. 2. Executive cognitive functioning in corticosteroid users in 
comparison to nonusers. Adjusted mean differences (95% CI) in 
unique design score between the single-type corticosteroid users, 
and nonusers as reference (a). The same analyses stratified for sub-
jects with either low or high physical component summary score 
as proxy for physical QoL (b), and for presence or absence of mood 
and/or anxiety disorders (c). Analyses are adjusted for age, sex, 
educational attainment, BMI, smoking, alcohol use, physical activ-
ity, cardiovascular diseases, and use of psychotropic drugs.
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Corticosteroid Use and Mood and Anxiety Disorders
Current mood and/or anxiety disorders were present 
in 11.1% of the total population, and were both more 
prevalent in corticosteroid users in comparison to nonus-
ers (both p < 0.001; Table 1). Stratification for the main 
route of corticosteroid administration revealed associa-
tions for local types with both mood disorders (OR 1.24 
[1.11–1.40]) and anxiety disorders (OR 1.18 [1.10–1.27], 
Table 2. Association between corticosteroid use and psychiatric disorders
Number Mood disorders Anxiety disorders
present, n (%) crude model adjusted modela present, n (%) crude model adjusted modela
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Nonusers 74,591 2,393 (3.2) Ref. Ref. 7,138 (9.6) Ref. Ref.
Overall 
users 9,001 409 (4.5) 1.44 1.29–1.60*** 1.26 1.13–1.41*** 1,074 (11.9) 1.28 1.20–1.37*** 1.17 1.09–1.26***
Route
Local 8,608 385 (4.5) 1.41 1.27–1.58*** 1.24 1.11–1.40*** 1,035 (12.0) 1.29 1.21–1.38*** 1.18 1.10–1.27***
Systemic 393 24 (6.1) 1.96 1.30–2.97** 1.58 1.02–2.44* 39 (9.9) 1.04 0.75–1.45 0.86 0.61–1.21
Single type
Systemic 280 18 (6.4) 2.07 1.28–3.35** 1.75 1.05–2.91* 28 (10.0) 1.05 0.71–1.55 0.89 0.59–1.34
Inhaled 3,248 182 (5.6) 1.79 1.53–2.09*** 1.40 1.19–1.65*** 421 (13.0) 1.41 1.27–1.56*** 1.19 1.06–1.33**
Nasal 2,142 75 (3.5) 1.10 0.87–1.38 1.06 0.83–1.35 249 (11.6) 1.24 1.09–1.42** 1.21 1.05–1.39**
Dermal 1,620 46 (2.8) 0.88 0.66–1.19 0.90 0.66–1.22 177 (10.9) 1.16 0.99–1.36 1.18 1.01–1.40*
Others 263 14 (5.3) 1.70 0.99–2.91 1.63 0.93–2.86 28 (10.6) 1.13 0.76–1.67 1.04 0.69–1.57* p < 0.050, ** p < 0.010, *** p < 0.001. The group of non-corticosteroid users is taken as reference. 
a The analyses are adjusted for age, sex, educational attainment, body mass index, smoking, alcohol use, physical activity, cardiovascular diseases, and 
use of psychotropic drugs. 
Table 3. Corticosteroid use and presence of mood and/or anxiety disorders by physical quality of life
Mood and/or anxiety disorders
low physical quality of life (n = 41,796) high physical quality of life (n = 41,796)
number present crude model adjusted modela numberpresent crude model adjusted modela
OR 95% CI OR 95%CI OR 95% CI OR 95% CI
Nonusers 36,011 4,740 (13.2) Ref. Ref. 38,580 3,324 (8.6) Ref. Ref.
Overall 
users 5,785 906 (15.7) 1.23 1.13–1.32*** 1.15 1.06–1.24** 3,216 331 (10.3) 1.22 1.08–1.37** 1.20 1.06–1.36**
Route
Local 5,444 858 (15.8) 1.23 1.14–1.34*** 1.16 1.06–1.26*** 3,164 329 (10.4) 1.23 1.09–1.39*** 1.21 1.07–1.37**
Systemic 341 48 (14.1) 1.08 0.80, 1.47 0.98 0.71–1.35 52 2 (3.8) 0.42 0.10–1.74 0.47 0.11–1.94
Single type
Systemic 238 35 (14.7) 1.14 0.79–1.63 1.07 0.73–1.56 42 2 (4.8) 0.53 0.13–2.20 0.55 0.13–2.30
Inhaled 2,248 372 (16.5) 1.31 1.17–1.47*** 1.15 1.01–1.29* 1,000 118 (11.8) 1.42 1.17–1.73*** 1.32 1.08–1.62**
Nasal 1,212 191 (15.8) 1.23 1.05–1.45** 1.23 1.04–1.45* 930 90 (9.7) 1.14 0.91–1.42 1.12 0.89–1.41
Dermal 882 126 (14.3) 1.10 0.91–1.33 1.11 0.91–1.36 738 68 (9.2) 1.08 0.84–1.39 1.17 0.91–1.52
Others 170 26 (15.3) 1.19 0.78–1.81 1.18 0.76–1.83 93 8 (8.6) 1.00 0.48–2.06 0.92 0.43–1.96* p < 0.050, ** p < 0.010, *** p < 0.001. The group of non-corticosteroid users is taken as reference. Mood and anxiety disorders are combined together 
due to otherwise small number of cases in users. 
a The analyses are adjusted for age, sex, educational attainment, body mass index, smoking, alcohol use, physical activity, cardiovascular diseases, and 
use of psychotropic drugs. 
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both p < 0.001; Table 2). Systemic corticosteroid use was 
only associated with mood disorders, which was especial-
ly evident in the single-type users (OR 1.75 [1.05–2.91], 
p = 0.031). Among users of local corticosteroids, users of 
only inhaled corticosteroids were more likely to have 
mood disorders (OR 1.40 [1.19–1.65], p < 0.001) and anx-
iety disorders (OR 1.19 [1.06–1.33], p = 0.002) in com-
parison to nonusers. For anxiety disorders, similar asso-
ciations were present in nasal corticosteroid users (OR 
1.21 [1.05–1.39], p = 0.007) and dermal corticosteroid us-
ers (OR 1.18 [1.01–1.40], p = 0.043). Interaction analyses 
for sex and age showed no significant differences. With 
subgroup analyses, inhaled corticosteroid use was found 
to be associated with increased likelihood for mood and/
or anxiety disorders in both subjects with low physical 
QoL (OR 1.15 [1.01–1.29], p = 0.030) as well as high phys-
ical QoL (OR 1.32 [1.08–1.62], p = 0.008; Table 3). Among 
users with low physical QoL, relatively high effect sizes 
were found for users of nasal corticosteroids and users of 
the group of other corticosteroids, although the differ-
ence was significant only in the former group. 
Sensitivity Analyses
Corticosteroid users had in general a higher hsCRP 
than nonusers (median [IQR] 1.50 [2.90] vs. 1.20 [2.10] 
mg/L, p < 0.001; Table 1). With regard to cognition, there 
was a negative association between hsCRP and unique 
design score (B = –0.087, SE = 0.022, p < 0.001). Never-
theless, the use of systemic as well as inhaled corticoste-
roids was persistently associated with significantly lower 
cognitive scores when adjusted for hsCRP (Table 4). Ad-
ditional adjustment for mood and anxiety disorders did 
not affect these results (data not shown). There was no 
association between hsCRP and the presence of mood 
and anxiety disorders.
Discussion
In the current study, we show that use of both system-
ic and local corticosteroids, particularly the inhaled types, 
is associated with a reduced executive cognitive function-
ing and a higher likelihood of mood and anxiety disor-
ders. With regard to the inhaled forms, these findings 
were persistent in both individuals with low and high 
physical QoL suggesting potential drug effects regardless 
of physical condition. Despite an inverse association be-
tween hsCRP levels and cognition, the use of systemic and 
inhaled types was independently associated with lower 
cognitive performance. 
A reduction in executive cognitive functioning in local 
and systemic corticosteroid users, as found in this study, 
could hint on corticosteroid effects on the brain. Although 
multiple studies have shown an association between cor-
ticosteroid use and central nervous system disorders, the 
pathophysiology of exogenous corticosteroid action on 
Table 4. Differences in cognition between users and nonusers with available hsCRP data (n = 45,395)
Number Unique design score
model 1 model 2
Nonusers 40,695 Ref. Ref.
Overall users 4,700 –1.12 (–1.76 to –0.48)*** –1.07 (–1.71 to –0.43)**
Route
Local 4,497 –0.94 (–1.59 to –0.28)** –0.89 (–1.55 to –0.24)**
Systemic 203 –5.18 (–8.10 to –2.25)*** –5.04 (–7.97 to –2.12)***
Single type
Systemic 153 –5.27 (–8.64 to –1.90)** –5.13 (–8.50 to –1.76)**
Inhaled 1,783 –2.33 (–3.34 to –1.32)*** –2.28 (–3.29 to –1.27)***
Nasal 1,078 –0.37 (–1.65 to 0.92) –0.33 (–1.61 to 0.96)
Dermal 856 0.99 (–0.45 to 2.42) 1.00 (–0.44 to 2.44)
Others 120 2.37 (–1.43 to 6.17) 2.39 (–1.41 to 6.19)** p < 0.010, *** p < 0.001.
Adjusted mean differences (95% CI) in total unique design score between corticosteroids users and nonusers (reference). Model 1 is 
adjusted for age, sex, educational attainment, body mass index, smoking, alcohol use, physical activity, cardiovascular diseases, and use 
of psychotropic drugs. Model 2 is additionally adjusted for hsCRP. 
Corticosteroids, Cognition, and 
Psychiatric Health
289Neuroendocrinology 2020;110:282–291
DOI: 10.1159/000501617
the brain is still not well understood [18]. Corticosteroids 
have been described to affect various aspects of brain 
physiology, including selective hippocampal atrophy [19], 
neuronal plasticity [20, 21], neurotoxicity [22], and neu-
rogenesis [23]. The hippocampus in particular is an im-
portant target of corticosteroids and strongly expresses 
both mineralocorticoid as well as glucocorticoid receptors 
[24–26]. Excess corticosteroids could lead to reversible 
and irreversible damage to hippocampal structure and 
thus contribute to cognitive impairment [26]. Another 
brain region that seems susceptible to corticosteroid ef-
fects is the medial prefrontal cortex. Chronic corticoste-
rone administration [27] and behavioral stress [28] have 
been demonstrated to result in a reorganization of apical 
dendrites in pyramidal neurons of the medial prefrontal 
cortex in rodent models. This reorganization may have 
functional consequences as reflected in glucocorticoid-in-
duced changes in cognition, working memory and stress-
related behavioral disorders [27–29]. Interestingly, the 
RFFT used as a measure of non-verbal fluency in the pres-
ent study is especially sensitive to function [30] and dys-
function [31] of the right frontal lobe. In line with this, a 
previous placebo-controlled, crossover, randomized trial 
with healthy subjects receiving supraphysiological oral 
hydrocortisone found that corticosteroids indeed induced 
cognitive impairments which were especially related to 
frontal lobe dysfunction [32]. It is therefore conceivable 
that in case of systemic availability of local corticosteroids, 
in particular of the inhaled forms, these regions would also 
be exposed to supraphysiological glucocorticoid levels 
and subsequently impaired in their functioning. 
We found that users of systemic and inhaled cortico-
steroids scored nearly 2–3 points lower on the RFFT 
when compared to nonusers. It is noteworthy to mention 
that these differences are relatively modest. Nevertheless, 
it is especially interesting that the outcomes point repeat-
edly in the same direction in all analyses for the systemic 
and the inhaled types. Among important contributors to 
RFFT score, age has consistently found to be negatively 
associated [12, 33] as was also observed in our cohort. In 
terms of clinical relevancy, the worse scores with inhaled 
and systemic corticosteroid use would on average corre-
spond to lower scores as found with an age increase of 4.3 
and 5.8 years, respectively, in our group of nonusers while 
controlling for other covariates.
Neuropsychiatric disorders are known to be one of the 
most prevalent and distressing adverse effects in users of 
systemic corticosteroids. Fardet and colleagues observed 
that approximately half of these users reported to suffer 
from neuropsychiatric complaints, including anxiety and 
depression, after they had started with corticosteroid 
treatment [34]. In addition, a small study with physically 
and mentally healthy subjects also showed behavioral 
changes in 75% of the participants after high-dose oral 
prednisone administration for 5 days [35]. Moreover, en-
dogenous Cushing’s syndrome has also frequently been 
linked with various psychopathologies [9, 36] among 
which mood and anxiety disorders as observed in the cur-
rent study. In that sense, it would be conceivable that the 
inhaled types could also lead to these disorders in case of 
systemic absorption. This would even be more expected, 
given the high glucocorticoid receptor binding affinity of 
the frequently administered inhaled forms which is com-
parable to nearly 10–20 times that of dexamethasone [37]. 
Interestingly, the unfavorable findings regarding cogni-
tion, mood and anxiety were especially evident in users of 
these types. However, it should be noted that the effect 
sizes are relatively small. Nevertheless, these and our pre-
vious findings of higher likelihood for metabolic syn-
drome, a higher BMI, and other cardiometabolic altera-
tions in users of inhaled corticosteroids [6] are in line 
with frequently observed features in systemic corticoste-
roids users and Cushing’s syndrome patients. These find-
ings are consistent with our hypothesis of systemic avail-
ability and effects of inhaled corticosteroids in which case 
both somatic and brain effects would be observed when 
exposed to supraphysiological dosages.
An important consideration in understanding the ef-
fect of corticosteroids on the brain is their penetration of 
the blood-brain barrier. While corticosteroids, in general, 
pass through cell membranes to enter the brain on ac-
count of their lipophilicity, cells comprising the blood-
brain barrier express proteins of the multidrug transport-
er system, which limit the access of exogenous molecules 
to the brain [24, 38]. Further functional studies are essen-
tial to demonstrate the access of the various exogenous 
corticosteroids to different brain areas and the implica-
tions for cognitive and psychiatric functioning. 
The strength of this work lies in the in-depth pheno-
typing, extensive assessment, and completeness for the 
outcome observations in large number of subjects from 
the general adult population. An important limitation to 
mention is the observational nature which hinders draw-
ing conclusions on causality and is prone to residual con-
founding. Moreover, we assessed only one aspect of the 
various cognitive functioning domains and merely in 
persons with no significant impairments with the Mini-
Mental State Examination. Finally, there were no data 
available on the cumulative dose exposure. However, our 
main findings are particularly driven by the inhaled forms 
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that are conceivably used in a chronic fashion giving the 
underlying often chronic indications such as asthma.
Conclusions
Commonly used local corticosteroids, in particular the 
inhaled types, and systemic corticosteroids are associated 
with reduced executive cognitive functioning and a high-
er likelihood of mood and anxiety disorders in the gen-
eral adult population. Future confirmatory studies are 
needed to ratify our findings and to prove temporality, 
while further research should also assess the associations 
with other cognitive processes and psychiatric disorders.
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